US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

0.7800

-0.0492-5.93%

Volume:95.40K

Turnover:76.54K

Market Cap:5.81M

PE:-0.08

High:0.8400

Open:0.7951

Low:0.7799

Close:0.8292

Loading ...

Overview Company News Filings

Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study

Pasithea Therapeutics Presents Updated Interim Data From Ongoing Phase 1 Study of Pas-004 at the Asco Annual Meeting 2025

THOMSON REUTERS

Tiago Marques, CEO of Pasithea Therapeutics, Reports Disposal of Common Shares

BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of Pas-004 in Adult Nf1 Patients and Activation of First Clinical Trial Site

THOMSON REUTERS

Press Release: Pasithea Therapeutics Announces Closing of $5 Million Public Offering

BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering

Pasithea Therapeutics Prices $5 Million Public Offering

MT Newswires Live

Pasithea Therapeutics 3.57M share Secondary priced at $1.40

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

THOMSON REUTERS

Pasithea- Pas-004 Demonstrated Clinically Meaningful Reductions in Perk Levels at Dose Levels That Are Well-Tolerated, Safe, With No Rash Observed

THOMSON REUTERS

Pasithea Therapeutics - Positive Interim Pharmacodynamic Data From Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients

THOMSON REUTERS

Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment

BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing

Pasithea Therapeutics Files for Offering up to 3.2 Mln Common Shares Together With Warrants - SEC Filing

THOMSON REUTERS

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004

Pasithea Therapeutics Corp - Enrollment Expected to Complete by End of 2025

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 From Its Phase 1 Trial of Pas-004 in Advanced Cancer Patients

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Psychedelic: Clearmind completes clinical site initiations for AUD trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KTTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.78,"timestamp":1749827052674,"preClose":0.8292,"halted":0,"volume":95403,"delay":0,"floatShares":6759041,"shares":7443600,"eps":-9.801436,"marketStatus":"Trading","change":-0.0492,"latestTime":"06-13 11:04:27 EDT","open":0.7951,"high":0.84,"low":0.7799,"amount":76542.57485952,"amplitude":0.072479,"askPrice":0.797,"askSize":372,"bidPrice":0.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.801436,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749844800000},"marketStatusCode":2,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.8292,"preHourTrading":{"tag":"盘前","latestPrice":0.825,"preClose":0.8292,"latestTime":"09:26 EDT","volume":3473,"amount":2866.5641888,"timestamp":1749821210916},"postHourTrading":{"tag":"盘后","latestPrice":0.84,"preClose":0.8292,"latestTime":"19:59 EDT","volume":3833,"amount":3170.5675,"timestamp":1749772753264},"volumeRatio":2.255637},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","floatShares":6759041,"roa":"-46.84%","roe":"-82.81%","lyrEps":-12.685715,"volumeRatio":2.255637,"shares":7443600,"dividePrice":0,"high":0.84,"amplitude":0.072479,"preClose":0.8292,"low":0.7799,"week52Low":0.7799,"pbRate":"0.45","psRate":"11.93","week52High":7.5,"institutionHeld":0,"latestPrice":0.78,"committee":-0.576271,"eps":-9.801436,"divideRate":0,"volume":95403,"delay":0,"ttmEps":-9.801436,"open":0.7951,"prevYearClose":3.15,"prevWeekClose":0.8858,"prevMonthClose":0.97,"prevQuarterClose":1.3,"fiveDayClose":0.8858,"twentyDayClose":0.8606,"sixtyDayClose":1.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540798208","title":"Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798208","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798208?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:36","pubTimestamp":1748867764,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced updated interim results from its ongoing dose escalation Phase 1 study evaluating PAS-004 in advanced cancer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-presents-updated-interim-data-from-phase-1-pas-004-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-presents-updated-interim-data-from-phase-1-pas-004-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","KTTA","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2540262760","title":"Pasithea Therapeutics Presents Updated Interim Data From Ongoing Phase 1 Study of Pas-004 at the Asco Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540262760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540262760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:02","pubTimestamp":1748865720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3JBHG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2535683498","title":"Tiago Marques, CEO of Pasithea Therapeutics, Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2535683498","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535683498?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:55","pubTimestamp":1747274155,"startTime":"0","endTime":"0","summary":"Tiago Marques, Chief Executive Officer and Director of Pasithea Therapeutics Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL1m91bN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2535812026","title":"BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2535812026","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535812026?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:06","pubTimestamp":1747224394,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial SiteMay 14 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA9DFBJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","KTTAW","BK4139"],"gpt_icon":0},{"id":"2535422970","title":"Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of Pas-004 in Adult Nf1 Patients and Activation of First Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2535422970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535422970?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:02","pubTimestamp":1747220520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA9DFBJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2533255962","title":"Press Release: Pasithea Therapeutics Announces Closing of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533255962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533255962?lang=en_us&edition=fundamental","pubTime":"2025-05-08 05:00","pubTimestamp":1746651600,"startTime":"0","endTime":"0","summary":"Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering. The Series C warrants have an exercise price of $1.40 per share, are exercisable upon issuance and will expire five years thereafter. The Series D warrants have an exercise price of $1.40 per share, are exercisable upon issuance and will expire 18 months thereafter. Simultaneously with the closing of the offering, certain investors exercised Series D warrants to purchase an aggregate of 914,286 shares of common stock, resulting in additional gross proceeds to the Company of approximately $1.3 million.The securities described above were offered pursuant to a registration statement on Form S-1  originally filed with the Securities and Exchange Commission  on May 1, 2025 and declared effective on May 6, 2025. The offering was made only by means of a prospectus, which is part of the effective registration statement. A final prospectus relating to the offering ha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PD","LENZ","BK4139","PK","CNS","LU1169589451.USD","LU1169590202.USD","BK4023","BK4135","KTTA","BK4218","BK4181"],"gpt_icon":0},{"id":"2533433654","title":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533433654","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533433654?lang=en_us&edition=fundamental","pubTime":"2025-05-07 00:18","pubTimestamp":1746548292,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public OfferingMay 6 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERINGSource text: ID:nGNX58PWjJFurther company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE2EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2533065947","title":"Pasithea Therapeutics Prices $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533065947","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533065947?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:38","pubTimestamp":1746545880,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Tuesday it priced a $5 million public offering consisting of nearly 3.6 million common shares, or pre-funded warrants, at $1.40 per share.The offering includes series C warrants, which expire in five years, and series D warrants, which expire in 18 months, both exercisable at $1.40 per share.The offering is expected to close around Wednesday, pending the fulfillment of customary closing conditions.The company plans to use the proceeds for general corporate purposes such as research, clinical trials, technology development, potential acquisitions, and working capital, the company said.Shares of the biotechnology company rose more than 35% in recent Tuesday trading.Price: 1.92, Change: +0.50, Percent Change: +35.21","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KTTA","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2533659448","title":"Pasithea Therapeutics 3.57M share Secondary priced at $1.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2533659448","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533659448?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:35","pubTimestamp":1746545733,"startTime":"0","endTime":"0","summary":"The gross proceeds to the company from the offering are expected to be approximately $5M, before deducting the placement agent’s fees and other off...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2533550826","title":"Pasithea Therapeutics Announces Pricing of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533550826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533550826?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:10","pubTimestamp":1746544214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE2EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2533925686","title":"Pasithea- Pas-004 Demonstrated Clinically Meaningful Reductions in Perk Levels at Dose Levels That Are Well-Tolerated, Safe, With No Rash Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2533925686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533925686?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:04","pubTimestamp":1746529444,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2533686590","title":"Pasithea Therapeutics - Positive Interim Pharmacodynamic Data From Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2533686590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533686590?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:04","pubTimestamp":1746529444,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2532591798","title":"Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532591798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532591798?lang=en_us&edition=fundamental","pubTime":"2025-05-02 09:48","pubTimestamp":1746150515,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment. Pasithea Therapeutics Corporation has released an investor presentation detailing its current corporate overview and ongoing projects. The presentation provides insights into the company's pipeline developments, including the clinical trial progress of its product candidate, PAS-004, for advanced cancer patients. It highlights the company's focus on advancing its clinical and preclinical candidates and discusses the design and conduct of its ongoing Phase 1 clinical trial. The presentation also addresses the company's plans for future operations, including the pursuit of new indications and the filing of regulatory documents. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL4Zty9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2532000524","title":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000524?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:21","pubTimestamp":1746116464,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC FilingMay 1  - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS FILES FOR OFFERING UP TO 3.2 MILLION COMMON SHARES TOGETHER WITH WARRANTS - SEC FILINGSource text: [ID:n0001213900-25-038088]Further company coverage: KTTA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R92EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2532070698","title":"Pasithea Therapeutics Files for Offering up to 3.2 Mln Common Shares Together With Warrants - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070698","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070698?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:30","pubTimestamp":1746106216,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R92EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2531789494","title":"Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789494?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:18","pubTimestamp":1745925516,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2531890227","title":"Pasithea Therapeutics Corp - Enrollment Expected to Complete by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531890227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531890227?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA24WKY2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2531786615","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 From Its Phase 1 Trial of Pas-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786615?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA24WKY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTAW","BK4139","KTTA"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4157","KTTAW","KTTA","AEIS","BK4139","BK4007","IE00B19Z4B17.USD","PK","BK4023","IE00B66KJ199.SGD","IE00B7SZL793.SGD","CNS","LU1169590202.USD","BK4135","PD","BK4218","IE0031619046.USD","BK4181","LU1169589451.USD","LENZ"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4168","RLMD","BK4202","BK4139","KTTA","ALID","PHRRF","MYCOF","BK4539","IXHL","MDXXF","MNMD","PBM","QNTM","GHRS","OPTHF","RVVTF","CYBN","BK4547","PSYGF","NUMIF","SPRC","DRUG","NRXP","CMND","BK4007","CMPS","SEEL","SILO","SNPX","ENTBF","FLHLF","ENVB","BETRF","AGNPF","MIRA","ATAI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"KTTA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-2.41},{"market":"US","date":"2024-08-13","symbol":"KTTA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-3.71},{"market":"US","date":"2024-05-14","symbol":"KTTA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.7},{"market":"US","date":"2024-03-28","symbol":"KTTA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-02","symbol":"KTTA","defaultRemindTime":1704205800000,"type":"split","dateTimestamp":1704171600000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KTTA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KTTA","date":"2025-06-12","current":-0.464438,"percent":0.650549,"low":-1093.683193,"twenty":-8.674986,"median":-0.773948,"eighty":-0.32736,"high":-0.082689,"avg":-38.97563,"sd":149.006661,"marketCap":6319596},"quantilePoints":[{"date":"2021-08-13","current":-1093.683193,"twenty":-1093.683193,"median":-1093.683193,"eighty":-1093.683193,"marketCap":67235268},{"date":"2021-09-17","current":-669.104496,"twenty":-1093.683193,"median":-756.194287,"eighty":-671.674393,"marketCap":41133868},{"date":"2021-09-24","current":-626.621673,"twenty":-1093.683193,"median":-671.674393,"eighty":-632.994101,"marketCap":38522194},{"date":"2021-10-01","current":-609.628538,"twenty":-891.189849,"median":-656.359653,"eighty":-608.804372,"marketCap":37477524},{"date":"2021-10-08","current":-556.525018,"twenty":-729.430106,"median":-641.490663,"eighty":-578.616078,"marketCap":34212932},{"date":"2021-10-15","current":-632.994095,"twenty":-687.639563,"median":-626.621673,"eighty":-571.393991,"marketCap":38913945},{"date":"2021-10-22","current":-571.393991,"twenty":-671.674393,"median":-609.628538,"eighty":-571.393991,"marketCap":35127017},{"date":"2021-10-29","current":-601.13197,"twenty":-670.132455,"median":-607.568124,"eighty":-571.393991,"marketCap":36955189},{"date":"2021-11-05","current":-537.407736,"twenty":-661.45759,"median":-596.894317,"eighty":-566.296057,"marketCap":33037678},{"date":"2021-11-12","current":-548.02845,"twenty":-653.810678,"median":-586.262981,"eighty":-556.525018,"marketCap":33690597},{"date":"2021-11-19","current":-10.979296,"twenty":-648.287908,"median":-575.642283,"eighty":-545.904304,"marketCap":31303839},{"date":"2021-11-26","current":-18.576783,"twenty":-642.340318,"median":-572.456064,"eighty":-536.133248,"marketCap":52965567},{"date":"2021-12-03","current":-21.49554,"twenty":-635.54307,"median":-571.393991,"eighty":-511.493207,"marketCap":61287438},{"date":"2021-12-10","current":-17.503511,"twenty":-631.294785,"median":-567.145715,"eighty":-26.651141,"marketCap":49905485},{"date":"2021-12-17","current":-11.361928,"twenty":-627.896161,"median":-558.649148,"eighty":-21.219169,"marketCap":32394789},{"date":"2021-12-23","current":-15.430727,"twenty":-624.92236,"median":-556.525018,"eighty":-19.683773,"marketCap":43995625},{"date":"2021-12-31","current":-13.588252,"twenty":-616.425792,"median":-549.090515,"eighty":-17.135016,"marketCap":38742416},{"date":"2022-01-07","current":-11.438698,"twenty":-609.628538,"median":-545.904304,"eighty":-14.877985,"marketCap":32613672},{"date":"2022-01-14","current":-10.59423,"twenty":-609.216455,"median":-536.345663,"eighty":-14.064224,"marketCap":30205951},{"date":"2022-01-21","current":-9.596223,"twenty":-607.568124,"median":-527.849104,"eighty":-13.434712,"marketCap":27360463},{"date":"2022-01-28","current":-8.598216,"twenty":-601.13197,"median":-505.545611,"eighty":-11.515468,"marketCap":24514975},{"date":"2022-02-04","current":-9.135604,"twenty":-599.00784,"median":-30.170526,"eighty":-11.361928,"marketCap":26047161},{"date":"2022-02-11","current":-9.442684,"twenty":-594.780793,"median":-25.717878,"eighty":-10.979296,"marketCap":26922696},{"date":"2022-02-18","current":-8.367907,"twenty":-594.759548,"median":-21.265231,"eighty":-10.238077,"marketCap":23858324},{"date":"2022-02-25","current":-7.830518,"twenty":-587.962294,"median":-19.883375,"eighty":-9.964718,"marketCap":22326138},{"date":"2022-03-04","current":-8.674986,"twenty":-582.86436,"median":-18.576783,"eighty":-9.442684,"marketCap":24733859},{"date":"2022-03-11","current":-9.212374,"twenty":-576.916767,"median":-17.273201,"eighty":-9.35056,"marketCap":26266045},{"date":"2022-03-18","current":-10.210381,"twenty":-575.642283,"median":-15.430727,"eighty":-9.35056,"marketCap":29111533},{"date":"2022-03-25","current":-10.287151,"twenty":-573.942966,"median":-14.739799,"eighty":-9.365914,"marketCap":29330417},{"date":"2022-04-01","current":-13.65563,"twenty":-571.81882,"median":-14.35595,"eighty":-9.42733,"marketCap":29680798},{"date":"2022-04-08","current":-13.126342,"twenty":-571.393991,"median":-13.905179,"eighty":-9.442684,"marketCap":28530380},{"date":"2022-04-14","current":-14.290775,"twenty":-571.393991,"median":-13.751639,"eighty":-9.488745,"marketCap":31061300},{"date":"2022-04-22","current":-12.279481,"twenty":-570.119513,"median":-13.588252,"eighty":-9.565515,"marketCap":26689710},{"date":"2022-04-29","current":-12.702912,"twenty":-567.995373,"median":-13.285128,"eighty":-9.596223,"marketCap":27610045},{"date":"2022-05-06","current":-10.967906,"twenty":-567.145715,"median":-13.126342,"eighty":-9.596223,"marketCap":23838973},{"date":"2022-05-13","current":-9.630924,"twenty":-565.871227,"median":-13.073413,"eighty":-9.617044,"marketCap":20933015},{"date":"2022-05-20","current":-6.517075,"twenty":-561.198116,"median":-13.020484,"eighty":-9.488745,"marketCap":20842597},{"date":"2022-05-27","current":-6.082361,"twenty":-557.37467,"median":-12.649983,"eighty":-9.335206,"marketCap":19452314},{"date":"2022-06-03","current":-7.244512,"twenty":-556.525018,"median":-12.385339,"eighty":-9.289144,"marketCap":23169050},{"date":"2022-06-10","current":-7.427281,"twenty":-556.525018,"median":-12.385339,"eighty":-9.135604,"marketCap":23753574},{"date":"2022-06-17","current":-7.427281,"twenty":-553.976043,"median":-12.279481,"eighty":-8.936003,"marketCap":23753574},{"date":"2022-06-24","current":-7.093053,"twenty":-549.727754,"median":-12.279481,"eighty":-8.69034,"marketCap":22684663},{"date":"2022-07-01","current":-7.281648,"twenty":-547.603621,"median":-11.976086,"eighty":-8.306491,"marketCap":23287818},{"date":"2022-07-08","current":-7.791364,"twenty":-545.904304,"median":-11.515468,"eighty":-8.191854,"marketCap":24917965},{"date":"2022-07-15","current":-9.147016,"twenty":-545.904304,"median":-11.435659,"eighty":-8.082629,"marketCap":29253549},{"date":"2022-07-22","current":-9.432861,"twenty":-543.780158,"median":-11.361928,"eighty":-8.166979,"marketCap":30167723},{"date":"2022-07-29","current":-9.473696,"twenty":-537.407736,"median":-11.086562,"eighty":-8.191854,"marketCap":30298319},{"date":"2022-08-05","current":-10.127054,"twenty":-535.28359,"median":-10.967906,"eighty":-8.214367,"marketCap":32387858},{"date":"2022-08-12","current":-10.780413,"twenty":-533.159461,"median":-10.725706,"eighty":-8.291137,"marketCap":34477398},{"date":"2022-08-19","current":-6.949802,"twenty":-522.538747,"median":-10.59423,"eighty":-8.082629,"marketCap":35642748},{"date":"2022-08-26","current":-6.194955,"twenty":-520.414601,"median":-10.479076,"eighty":-7.830518,"marketCap":31771438},{"date":"2022-09-02","current":-5.986721,"twenty":-505.545611,"median":-10.363921,"eighty":-7.791364,"marketCap":30703491},{"date":"2022-09-09","current":-6.455247,"twenty":-497.049053,"median":-10.238077,"eighty":-7.500098,"marketCap":33106373},{"date":"2022-09-16","current":-6.559364,"twenty":-125.08671,"median":-10.210381,"eighty":-7.427135,"marketCap":33640346},{"date":"2022-09-23","current":-6.194955,"twenty":-28.696546,"median":-10.208724,"eighty":-7.354465,"marketCap":31771438},{"date":"2022-09-30","current":-6.559364,"twenty":-26.296891,"median":-10.091948,"eighty":-7.310774,"marketCap":33640346},{"date":"2022-10-07","current":-6.403188,"twenty":-25.76283,"median":-9.980072,"eighty":-7.237376,"marketCap":32839386},{"date":"2022-10-14","current":-6.507305,"twenty":-25.410799,"median":-9.903302,"eighty":-7.06116,"marketCap":33373360},{"date":"2022-10-21","current":-5.518195,"twenty":-22.263238,"median":-9.630924,"eighty":-6.814917,"marketCap":28300609},{"date":"2022-10-28","current":-5.622312,"twenty":-21.127045,"median":-9.596223,"eighty":-6.757186,"marketCap":28834583},{"date":"2022-11-04","current":-6.159301,"twenty":-20.175099,"median":-9.555365,"eighty":-6.611422,"marketCap":31588583},{"date":"2022-11-11","current":-5.988209,"twenty":-19.837313,"median":-9.494114,"eighty":-6.559364,"marketCap":30711122},{"date":"2022-11-18","current":-3.744034,"twenty":-19.683773,"median":-9.442684,"eighty":-6.515619,"marketCap":30658474},{"date":"2022-11-25","current":-3.607588,"twenty":-19.007296,"median":-9.432861,"eighty":-6.507305,"marketCap":29541174},{"date":"2022-12-02","current":-3.679026,"twenty":-18.521192,"median":-9.392026,"eighty":-6.455247,"marketCap":30126148},{"date":"2022-12-09","current":-3.500432,"twenty":-17.895759,"median":-9.365914,"eighty":-6.382365,"marketCap":28663714},{"date":"2022-12-16","current":-2.714621,"twenty":-17.22714,"median":-9.310356,"eighty":-6.278248,"marketCap":22229002},{"date":"2022-12-23","current":-2.062755,"twenty":-16.305902,"median":-9.289144,"eighty":-6.245813,"marketCap":16891117},{"date":"2022-12-30","current":-2.292069,"twenty":-15.661036,"median":-9.289144,"eighty":-6.194955,"marketCap":18768883},{"date":"2023-01-06","current":-2.309214,"twenty":-15.369311,"median":-9.229503,"eighty":-6.161226,"marketCap":18909276},{"date":"2023-01-13","current":-2.488168,"twenty":-15.06293,"median":-9.179695,"eighty":-6.142896,"marketCap":20374665},{"date":"2023-01-20","current":-2.447802,"twenty":-14.820063,"median":-9.135604,"eighty":-6.090838,"marketCap":20044125},{"date":"2023-01-27","current":-2.489236,"twenty":-14.816569,"median":-8.982065,"eighty":-6.045239,"marketCap":20383410},{"date":"2023-02-03","current":-2.421728,"twenty":-14.663029,"median":-8.86691,"eighty":-5.986721,"marketCap":19830610},{"date":"2023-02-10","current":-2.088826,"twenty":-14.35595,"median":-8.697833,"eighty":-5.934662,"marketCap":17104603},{"date":"2023-02-17","current":-2.096687,"twenty":-14.290775,"median":-8.636601,"eighty":-5.726429,"marketCap":17168979},{"date":"2023-02-24","current":-1.752716,"twenty":-14.158667,"median":-8.534493,"eighty":-5.622312,"marketCap":14352331},{"date":"2023-03-03","current":-1.780577,"twenty":-14.064224,"median":-8.291137,"eighty":-5.171792,"marketCap":14580470},{"date":"2023-03-10","current":-1.729249,"twenty":-13.818964,"median":-8.20311,"eighty":-3.679026,"marketCap":14160167},{"date":"2023-03-17","current":-1.535904,"twenty":-13.745731,"median":-8.082629,"eighty":-3.607588,"marketCap":12576935},{"date":"2023-03-24","current":-1.428748,"twenty":-13.672862,"median":-7.885734,"eighty":-3.570084,"marketCap":11699475},{"date":"2023-03-31","current":-1.339451,"twenty":-13.601728,"median":-7.830518,"eighty":-3.500432,"marketCap":10968258},{"date":"2023-04-05","current":-1.428391,"twenty":-13.526836,"median":-7.810941,"eighty":-3.465357,"marketCap":11696550},{"date":"2023-04-14","current":-0.749882,"twenty":-13.39605,"median":-7.718547,"eighty":-2.874212,"marketCap":10450696},{"date":"2023-04-21","current":-0.836681,"twenty":-13.316885,"median":-7.500098,"eighty":-2.62461,"marketCap":11660364},{"date":"2023-04-28","current":-0.656147,"twenty":-13.211028,"median":-7.436975,"eighty":-2.543242,"marketCap":9144359},{"date":"2023-05-05","current":-0.581159,"twenty":-13.126342,"median":-7.426917,"eighty":-2.49638,"marketCap":8099289},{"date":"2023-05-12","current":-0.674894,"twenty":-13.126342,"median":-7.354465,"eighty":-2.482807,"marketCap":9405626},{"date":"2023-05-18","current":-0.558853,"twenty":-13.126342,"median":-7.354465,"eighty":-2.427442,"marketCap":8885704},{"date":"2023-05-26","current":-0.600098,"twenty":-13.126342,"median":-7.33626,"eighty":-2.358077,"marketCap":9541485},{"date":"2023-06-02","current":-0.575285,"twenty":-13.062827,"median":-7.281648,"eighty":-2.303499,"marketCap":9146971},{"date":"2023-06-09","current":-0.79531,"twenty":-13.020484,"median":-7.244512,"eighty":-2.280424,"marketCap":12645342},{"date":"2023-06-16","current":-0.761131,"twenty":-13.020484,"median":-7.134559,"eighty":-2.147122,"marketCap":12101905},{"date":"2023-06-23","current":-0.709863,"twenty":-12.978141,"median":-7.063199,"eighty":-2.090973,"marketCap":11286751},{"date":"2023-06-30","current":-0.788737,"twenty":-12.808769,"median":-6.990382,"eighty":-2.071684,"marketCap":12540835},{"date":"2023-07-07","current":-0.838033,"twenty":-12.724083,"median":-6.819656,"eighty":-2.046396,"marketCap":13324637},{"date":"2023-07-14","current":-0.755052,"twenty":-12.639397,"median":-6.767598,"eighty":-1.946312,"marketCap":12005237},{"date":"2023-07-21","current":-0.974419,"twenty":-12.512368,"median":-6.767598,"eighty":-1.782717,"marketCap":15493156},{"date":"2023-07-28","current":-0.971133,"twenty":-12.385339,"median":-6.650466,"eighty":-1.757289,"marketCap":15440903},{"date":"2023-08-04","current":-0.973269,"twenty":-12.385339,"median":-6.611422,"eighty":-1.737636,"marketCap":15474868},{"date":"2023-08-11","current":-1.029301,"twenty":-12.385339,"median":-6.559364,"eighty":-1.647346,"marketCap":16365772},{"date":"2023-08-18","current":-0.922144,"twenty":-12.385339,"median":-6.559364,"eighty":-1.54019,"marketCap":15680815},{"date":"2023-08-25","current":-0.936135,"twenty":-12.342996,"median":-6.513434,"eighty":-1.443036,"marketCap":15918720},{"date":"2023-09-01","current":-0.930908,"twenty":-12.279481,"median":-6.507305,"eighty":-1.400387,"marketCap":15829832},{"date":"2023-09-07","current":-0.9532,"twenty":-12.279481,"median":-6.507305,"eighty":-1.339451,"marketCap":16208912},{"date":"2023-09-15","current":-0.799458,"twenty":-12.279481,"median":-6.507305,"eighty":-1.028381,"marketCap":13594571},{"date":"2023-09-22","current":-0.544841,"twenty":-12.279481,"median":-6.455247,"eighty":-0.986118,"marketCap":9264880},{"date":"2023-09-29","current":-0.551575,"twenty":-12.189568,"median":-6.403188,"eighty":-0.977377,"marketCap":9379390},{"date":"2023-10-06","current":-0.518763,"twenty":-12.037502,"median":-6.320693,"eighty":-0.970344,"marketCap":8821415},{"date":"2023-10-13","current":-0.530699,"twenty":-11.976086,"median":-6.247013,"eighty":-0.956072,"marketCap":9024389},{"date":"2023-10-20","current":-0.575911,"twenty":-11.699715,"median":-6.247013,"eighty":-0.93715,"marketCap":9793212},{"date":"2023-10-23","current":-0.575911,"twenty":-11.607592,"median":-6.247013,"eighty":-0.935766,"marketCap":9793212},{"date":"2023-11-03","current":-0.39211,"twenty":-11.454052,"median":-6.205643,"eighty":-0.929985,"marketCap":6667719},{"date":"2023-11-10","current":-0.459259,"twenty":-11.438698,"median":-6.194955,"eighty":-0.92073,"marketCap":7809566},{"date":"2023-11-17","current":-0.390317,"twenty":-11.433836,"median":-6.159301,"eighty":-0.839196,"marketCap":6257237},{"date":"2023-11-24","current":-0.402144,"twenty":-11.390205,"median":-6.151098,"eighty":-0.827299,"marketCap":6446851},{"date":"2023-12-01","current":-0.42372,"twenty":-11.361928,"median":-6.10227,"eighty":-0.805526,"marketCap":6792739},{"date":"2023-12-08","current":-0.428009,"twenty":-11.315866,"median":-6.090838,"eighty":-0.797799,"marketCap":6861499},{"date":"2023-12-15","current":-0.482209,"twenty":-11.185028,"median":-6.067797,"eighty":-0.787784,"marketCap":7730387},{"date":"2023-12-22","current":-0.37173,"twenty":-11.080219,"median":-6.002517,"eighty":-0.7805,"marketCap":5959274},{"date":"2023-12-29","current":-0.506905,"twenty":-11.039738,"median":-5.988209,"eighty":-0.774737,"marketCap":8126282},{"date":"2024-01-05","current":-0.490144,"twenty":-10.994407,"median":-5.986721,"eighty":-0.773619,"marketCap":7857593},{"date":"2024-01-12","current":-0.487408,"twenty":-10.970184,"median":-5.986721,"eighty":-0.764089,"marketCap":7813732},{"date":"2024-01-19","current":-0.454914,"twenty":-10.929162,"median":-5.874148,"eighty":-0.758896,"marketCap":7292817},{"date":"2024-01-26","current":-0.452965,"twenty":-10.829581,"median":-5.726429,"eighty":-0.751007,"marketCap":7261562},{"date":"2024-02-02","current":-0.428919,"twenty":-10.714765,"median":-5.67437,"eighty":-0.72911,"marketCap":6876084},{"date":"2024-02-09","current":-0.378229,"twenty":-10.624938,"median":-5.600708,"eighty":-0.690979,"marketCap":6063456},{"date":"2024-02-16","current":-0.470303,"twenty":-10.59423,"median":-5.518195,"eighty":-0.661662,"marketCap":7539522},{"date":"2024-02-23","current":-0.467912,"twenty":-10.588724,"median":-3.750463,"eighty":-0.651122,"marketCap":7501183},{"date":"2024-03-01","current":-0.519902,"twenty":-10.555264,"median":-3.679026,"eighty":-0.62303,"marketCap":8334648},{"date":"2024-03-08","current":-0.467918,"twenty":-10.486753,"median":-3.607588,"eighty":-0.60253,"marketCap":7501287},{"date":"2024-03-15","current":-0.467912,"twenty":-10.440691,"median":-3.607588,"eighty":-0.583874,"marketCap":7501183},{"date":"2024-03-22","current":-0.466066,"twenty":-10.409983,"median":-3.57187,"eighty":-0.577049,"marketCap":7471595},{"date":"2024-03-28","current":-0.464662,"twenty":-10.348567,"median":-3.536865,"eighty":-0.575543,"marketCap":7449091},{"date":"2024-04-05","current":-0.57144,"twenty":-10.277336,"median":-3.500432,"eighty":-0.575034,"marketCap":9121131},{"date":"2024-04-12","current":-0.499602,"twenty":-10.232538,"median":-3.465071,"eighty":-0.559641,"marketCap":7974474},{"date":"2024-04-19","current":-0.466948,"twenty":-10.210381,"median":-2.953758,"eighty":-0.555795,"marketCap":7453267},{"date":"2024-04-26","current":-0.472826,"twenty":-10.210381,"median":-2.714621,"eighty":-0.546188,"marketCap":7547084},{"date":"2024-05-03","current":-0.451927,"twenty":-10.210381,"median":-2.602107,"eighty":-0.539063,"marketCap":7213511},{"date":"2024-05-10","current":-0.501555,"twenty":-10.21005,"median":-2.572103,"eighty":-0.531663,"marketCap":8005642},{"date":"2024-05-17","current":-0.416074,"twenty":-10.193701,"median":-2.505399,"eighty":-0.520528,"marketCap":6775697},{"date":"2024-05-24","current":-0.419288,"twenty":-10.1323,"median":-2.491379,"eighty":-0.517907,"marketCap":6828026},{"date":"2024-05-31","current":-0.374766,"twenty":-10.127054,"median":-2.488168,"eighty":-0.505605,"marketCap":6103000},{"date":"2024-06-07","current":-0.36451,"twenty":-10.056842,"median":-2.456196,"eighty":-0.501555,"marketCap":5935976},{"date":"2024-06-14","current":-0.365112,"twenty":-10.047676,"median":-2.425835,"eighty":-0.493908,"marketCap":5945783},{"date":"2024-06-21","current":-0.314054,"twenty":-10.006197,"median":-2.408333,"eighty":-0.492726,"marketCap":5114314},{"date":"2024-06-28","current":-0.336969,"twenty":-9.980072,"median":-2.377973,"eighty":-0.490144,"marketCap":5487484},{"date":"2024-07-05","current":-0.331844,"twenty":-9.956506,"median":-2.333681,"eighty":-0.487408,"marketCap":5404024},{"date":"2024-07-12","current":-0.336329,"twenty":-9.912764,"median":-2.294926,"eighty":-0.482209,"marketCap":5477052},{"date":"2024-07-15","current":-0.358751,"twenty":-9.903302,"median":-2.293497,"eighty":-0.482209,"marketCap":5842188},{"date":"2024-08-02","current":-0.320954,"twenty":-9.903302,"median":-2.292069,"eighty":-0.481169,"marketCap":5226672},{"date":"2024-08-09","current":-0.310704,"twenty":-9.891593,"median":-2.279389,"eighty":-0.474405,"marketCap":5059752},{"date":"2024-08-16","current":-0.292199,"twenty":-9.80199,"median":-2.153123,"eighty":-0.473282,"marketCap":4788508},{"date":"2024-08-23","current":-0.299561,"twenty":-9.623984,"median":-2.117225,"eighty":-0.472794,"marketCap":4909164},{"date":"2024-08-30","current":-0.300103,"twenty":-9.596223,"median":-2.088826,"eighty":-0.470393,"marketCap":4918039},{"date":"2024-09-06","current":-0.272682,"twenty":-9.596223,"median":-2.071684,"eighty":-0.467918,"marketCap":4468666},{"date":"2024-09-13","current":-0.251339,"twenty":-9.596223,"median":-2.055611,"eighty":-0.466948,"marketCap":4118899},{"date":"2024-09-20","current":-0.305811,"twenty":-9.556182,"median":-2.005265,"eighty":-0.464662,"marketCap":5011588},{"date":"2024-09-27","current":-0.372708,"twenty":-9.555365,"median":-1.857015,"eighty":-0.464013,"marketCap":6107873},{"date":"2024-10-04","current":-0.333462,"twenty":-9.519453,"median":-1.780577,"eighty":-0.462388,"marketCap":5464719},{"date":"2024-10-11","current":-0.307723,"twenty":-9.514531,"median":-1.762986,"eighty":-0.459259,"marketCap":5042911},{"date":"2024-10-18","current":-0.254206,"twenty":-9.473696,"median":-1.752716,"eighty":-0.454914,"marketCap":4165883},{"date":"2024-10-25","current":-0.257597,"twenty":-9.473696,"median":-1.739733,"eighty":-0.453887,"marketCap":4221452},{"date":"2024-10-31","current":-0.251858,"twenty":-9.448886,"median":-1.696995,"eighty":-0.452009,"marketCap":4127410},{"date":"2024-11-08","current":-0.232092,"twenty":-9.442684,"median":-1.64306,"eighty":-0.451927,"marketCap":3803486},{"date":"2024-11-15","current":-0.264925,"twenty":-9.434826,"median":-1.559122,"eighty":-0.448416,"marketCap":4179209},{"date":"2024-11-22","current":-0.255291,"twenty":-9.400193,"median":-1.53519,"eighty":-0.441407,"marketCap":4027237},{"date":"2024-11-29","current":-0.248066,"twenty":-9.392026,"median":-1.464467,"eighty":-0.436176,"marketCap":3913259},{"date":"2024-12-06","current":-0.22639,"twenty":-9.392026,"median":-1.42857,"eighty":-0.428919,"marketCap":3571324},{"date":"2024-12-13","current":-0.214348,"twenty":-9.376359,"median":-1.339451,"eighty":-0.427079,"marketCap":3381360},{"date":"2024-12-20","current":-0.214348,"twenty":-9.365914,"median":-1.339272,"eighty":-0.42489,"marketCap":3381360},{"date":"2024-12-27","current":-0.223982,"twenty":-9.343691,"median":-1.028151,"eighty":-0.42257,"marketCap":3533331},{"date":"2025-01-03","current":-0.235221,"twenty":-9.310356,"median":-1.010569,"eighty":-0.421624,"marketCap":3710631},{"date":"2025-01-10","current":-0.224785,"twenty":-9.310356,"median":-0.986085,"eighty":-0.419171,"marketCap":3545995},{"date":"2025-01-17","current":-0.196687,"twenty":-9.310356,"median":-0.982799,"eighty":-0.415922,"marketCap":3102746},{"date":"2025-01-24","current":-0.199898,"twenty":-9.293386,"median":-0.974419,"eighty":-0.403234,"marketCap":3153403},{"date":"2025-01-31","current":-0.18063,"twenty":-9.289144,"median":-0.972201,"eighty":-0.402144,"marketCap":2849460},{"date":"2025-02-07","current":-0.1718,"twenty":-9.289144,"median":-0.961273,"eighty":-0.392063,"marketCap":2710153},{"date":"2025-02-14","current":-0.117209,"twenty":-9.289144,"median":-0.955593,"eighty":-0.387742,"marketCap":1848983},{"date":"2025-02-21","current":-0.108378,"twenty":-9.27737,"median":-0.940824,"eighty":-0.3827,"marketCap":1709676},{"date":"2025-02-28","current":-0.097942,"twenty":-9.24551,"median":-0.936135,"eighty":-0.373943,"marketCap":1545040},{"date":"2025-03-07","current":-0.097139,"twenty":-9.219226,"median":-0.930908,"eighty":-0.369851,"marketCap":1532376},{"date":"2025-03-14","current":-0.083491,"twenty":-9.212374,"median":-0.928755,"eighty":-0.36451,"marketCap":1317084},{"date":"2025-03-21","current":-0.094731,"twenty":-9.173159,"median":-0.922298,"eighty":-0.358765,"marketCap":1494383},{"date":"2025-03-28","current":-0.256818,"twenty":-9.140169,"median":-0.914919,"eighty":-0.347994,"marketCap":3570947},{"date":"2025-04-04","current":-0.24709,"twenty":-9.135604,"median":-0.83876,"eighty":-0.336713,"marketCap":3435684},{"date":"2025-04-11","current":-0.311294,"twenty":-9.135604,"median":-0.828668,"eighty":-0.333105,"marketCap":4328420},{"date":"2025-04-17","current":-0.266546,"twenty":-9.074188,"median":-0.824365,"eighty":-0.330695,"marketCap":3706210},{"date":"2025-04-25","current":-0.334642,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"marketCap":4653052},{"date":"2025-05-02","current":-0.29573,"twenty":-8.951357,"median":-0.80139,"eighty":-0.323462,"marketCap":4111999},{"date":"2025-05-09","current":-0.417852,"twenty":-8.874587,"median":-0.792023,"eighty":-0.321722,"marketCap":5810061},{"date":"2025-05-16","current":-0.374587,"twenty":-8.797817,"median":-0.788244,"eighty":-0.322912,"marketCap":5208477},{"date":"2025-05-23","current":-0.41854,"twenty":-8.730186,"median":-0.783386,"eighty":-0.323462,"marketCap":5695070},{"date":"2025-05-30","current":-0.418096,"twenty":-8.693264,"median":-0.780083,"eighty":-0.324385,"marketCap":5689018},{"date":"2025-06-06","current":-0.481396,"twenty":-8.674986,"median":-0.774113,"eighty":-0.325566,"marketCap":6550347},{"date":"2025-06-12","current":-0.464438,"twenty":-8.674986,"median":-0.773948,"eighty":-0.32736,"marketCap":6319596}],"updateTime":1749810784927}}}